Jan-Philipp Cieslik

Mr. Jan-Philipp Cieslik

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
TFTanja Fehm
Tanja Fehm
VMVolkmar Mueller
Volkmar Mueller
MBMaggie Banys-Paluchowski
Maggie Banys-Paluchowski
PFPeter A Fasching
Peter A Fasching
TFThomas W P Friedl
Thomas W P Friedl
FGfor the DETECT Study Group
for the DETECT Study Group
The phenotypes of tumor cells change during disease progression, but invasive rebiopsies of metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative metastatic breast cancer (MBC) patients with HER2-positive circulating tumor cells (CTCs) benefit from a HER2-targeted therapy. The open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited from March 2012 until September 2019 with a follow-up duration of 19.5 months. It was a multicenter clinical trial with 94 participating German study centers. A total of 2137 patients with HER2-negative MBC were screened for HER2-positive CTCs with a final modified intention-to-treat population of 101 patients. Eligible patients were randomized to standard therapy with or without lapatinib. Primary study endpoints included CTC clearance (no CTCs at the end of treatment) and secondary endpoints were progression-free survival, overall survival (OS), and safety. In both treatment arms CTC clearance at first follow-up visit—although not being significantly different for both arms at any time point—was significantly associated with improved OS (42.4 vs 14.1 months; P = 0.002). Patients treated additionally with lapatinib had a significantly improved OS over patients receiving standard treatment (20.5 vs 9.1 months, P = 0.009). DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for stratification of MBC cancer patients to HER2-targeting therapies. The OS benefit could be related to lapatinib, but further studies are required to prove this clinical observation. ClinicalTrials.gov Registration Number: NCT01619111.

13 July 2020 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
HAHannah Asperger
Hannah Asperger
NSNadia Stamm
Nadia Stamm
BGBerthold Gierke
Berthold Gierke
Michal PawlakMichal Pawlak
Michal Pawlak
UHUte Hofmann
Ute Hofmann
MLMarina Ludescher
Marina Ludescher
Background: PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breast carcinogenesis. Nevertheless, little is known about the mechanisms by which PGRMC1 drives tumor progression. The aim of our study was to investigate the involvement of PGRMC1 in cholesterol metabolism to detect new mechanisms by which PGRMC1 can increase lipid metabolism and alter cancer-related signaling pathways leading to breast cancer progression. Methods: The effect of PGRMC1 overexpression and silencing on cellular proliferation was examined in vitro and in a xenograft mouse model. Next, we investigated the interaction of PGRMC1 with enzymes involved in the cholesterol synthesis pathway such as CYP51, FDFT1, and SCD1. Further, the impact of PGRMC1 expression on lipid levels and expression of enzymes involved in lipid homeostasis was examined. Additionally, we assessed the role of PGRMC1 in key cancer-related signaling pathways including EGFR/HER2 and ERα signaling. Results: Overexpression of PGRMC1 resulted in significantly enhanced proliferation. PGRMC1 interacted with key enzymes of the cholesterol synthesis pathway, alters the expression of proteins, and results in increased lipid levels. PGRMC1 also influenced lipid raft formation leading to altered expression of growth receptors in membranes of breast cancer cells. Analysis of activation of proteins revealed facilitated ERα and EGFR activation and downstream signaling dependent on PGRMC1 overexpression in hormone receptor-positive breast cancer cells. Depletion of cholesterol and fatty acids induced by statins reversed this growth benefit. Conclusion: PGRMC1 may mediate proliferation and progression of breast cancer cells potentially by altering lipid metabolism and by activating key oncogenic signaling pathways, such as ERα expression and activation, as well as EGFR signaling. Our present study underlines the potential of PGRMC1 as a target for anti-cancer therapy.

29 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AFAndré Franken
André Franken
BBBianca Behrens
Bianca Behrens
FRFlorian Reinhardt
Florian Reinhardt
LYLiwen Yang
Liwen Yang
MRMahdi Rivandi
Mahdi Rivandi
HNHans Neubauer
Hans Neubauer
Background: The analysis of liquid biopsies, e.g., circulating tumor cells (CTCs) is an appealing diagnostic concept for targeted therapy selection. In this proof-of-concept study, we aimed to perform multiparametric analyses of CTCs to select targeted therapies for metastatic breast cancer patients. Methods: First, CTCs of five metastatic breast cancer patients were analyzed by whole exome sequencing (WES). Based on the results, one patient was selected and monitored by longitudinal and multiparametric liquid biopsy analyses over more than three years, including WES, RNA profiling, and in vitro drug testing of CTCs. Results: Mutations addressable by targeted therapies were detected in all patients, including mutations that were not detected in biopsies of the primary tumor. For the index patient, the clonal evolution of the tumor cells was retraced and resistance mechanisms were identified. The AKT1 E17K mutation was uncovered as the driver of the metastatic process. Drug testing on the patient’s CTCs confirmed the efficacy of drugs targeting the AKT1 pathway. During a targeted therapy chosen based on the CTC characterization and including the mTOR inhibitor everolimus, CTC numbers dropped by 97.3% and the disease remained stable as determined by computer tomography/magnetic resonance imaging. Conclusion: These results illustrate the strength of a multiparametric CTC analysis to choose and validate targeted therapies to optimize cancer treatment in the future. Furthermore, from a scientific point of view, such studies promote the understanding of the biology of CTCs during different treatment regimens.

1 August 2021 in Translational Oncology
Verified
Journal Article
Open access
HAHannah Asperger
Hannah Asperger
JCJan-Philipp Cieslik
Jan-Philipp Cieslik
BAB. Alberter
B. Alberter
CKC. Köstler
C. Köstler
BPBernhard Michael Polzer
Bernhard Michael Polzer
HNHans Neubauer
Hans Neubauer
Liquid Biopsy (LB) in the form of e.g., circulating tumor cells (CTCs) is a promising non-invasive approach to support current therapeutic cancer management. However, the proof of clinical utility of CTCs in informing therapeutic decision-making for e.g., breast cancer in clinical trials and associated translational research projects is facing the issues of low CTC positivity rates and low CTC numbers - even in the metastasized situation. To compensate for this dilemma, clinical CTC trials are designed as large multicenter endeavors with decentralized sample collection, processing and storage of products, making data management highly important to enable high-quality translational CTC research. In the DETECT clinical CTC trials we aimed at developing a custom-made, browser-based virtual database to harmonize and organize both decentralized processing and storage of LB specimens and to enable the collection of clinically meaningful LB sample. ViBiBa processes data from various sources, harmonizes the data and creates an easily searchable multilayered database. An open-source virtual bio-banking web-application termed ViBiBa was created, which automatically processes data from multiple non-standardized sources. These data are automatically checked and merged into one centralized databank and are providing the opportunity to extract clinically relevant patient cohorts and CTC sample collections. ViBiBa, which is a highly flexible tool that allows for decentralized sample storage of liquid biopsy specimens, facilitates a solution which promotes collaboration in a user-friendly, federalist and highly structured way. The source code is available under the MIT license from https://vibiba.com or https://github.com/asperciesl/ViBiBa.

12 February 2026 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
JCJan-Philipp Cieslik
Jan-Philipp Cieslik
XXXiaoye Xia
Xiaoye Xia
ASAli Salehi-Reyhani
Ali Salehi-Reyhani
Automating the isolation of rare cells such as circulating tumour cells (CTCs) within crowded microfluidic environments remains a bottleneck in liquid biopsy workflows. Optical tweezers offer contact-free, selective manipulation but traditionally rely on expert operators. We present MaGIC-OT (machine-guided isolation of cells using optical tweezers), a platform that integrates classical path planning and deep reinforcement learning (DRL) to automate single-cell manipulation inside a microfluidic chip. We built a high-fidelity simulation to train and benchmark control policies and show that cooperative, human-in-the-loop training improves DRL performance. Trained agents outperform expert users in speed and isolation success in silico, and we demonstrate proof-of-concept isolation of a cancer cell from a spiked blood sample on-chip. MaGIC-OT provides a flexible framework for intelligent optical manipulation, aligning microfluidic device design with autonomous control strategies and offering a pathway toward high-purity, label-free single-cell workflows.

11 December 2024 in Frauenheilkunde up2date
Verified
Journal Article
Closed access
PDF file
TFTanja Fehm
Tanja Fehm
CLChristiane Leidinger
Christiane Leidinger
JCJan-Philipp Cieslik
Jan-Philipp Cieslik
AFAndré Franken
André Franken
BBBianca Behrens
Bianca Behrens
Zirkulierende Tumor-DNA, CTCs und ctDNA, wird bereits erfolgreich im klinischen Alltag zur Prognoseprädiktion beim primären und metastasierten Mammakarzinom eingesetzt. In Zukunft wird der Einsatz der Liquid Biopsy möglicherweise noch deutlich zunehmen, da es derzeit viele vielversprechende Studien gibt. Im Rahmen dieses Artikels soll ein umfassender Blick auf den klinischen Einsatz von CTCs und ctDNA gerichtet werden unter Berücksichtigung der aktuellen Studienlage. Article published online: 11 December 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany